Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DX1002 in advanced hepatocellular carcinoma or gastric cancer
ChiCTR2400080296Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DX1002 in hepatocellular carcinoma (HCC) and gastric cancer (GC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: progression-free survival and adverse events. Started Jan 2024; status: recruiting.
02
Drugs
DX1002
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2400080296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080296.